EP Patent

EP4714503A2 — Amorphous solid dispersions of dasatinib and uses thereof

Assigned to Handa Therapeutics LLC · Expires 2026-03-25 · 0y expired

What this patent protects

An amorphous solid dispersion comprising dasatinib and one or more polymers; wherein the one or more polymers comprises a polymer that exhibits pH-dependent solubility.

USPTO Abstract

An amorphous solid dispersion comprising dasatinib and one or more polymers; wherein the one or more polymers comprises a polymer that exhibits pH-dependent solubility.

Drugs covered by this patent

Patent Metadata

Patent number
EP4714503A2
Jurisdiction
EP
Classification
—
Expires
2026-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Handa Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.